Literature DB >> 15100517

Gastroesophageal reflux disease: then and now.

Irvin M Modlin1, Steven F Moss, Mark Kidd, Kevin D Lye.   

Abstract

Although Galen first described esophagitis almost 2000 years ago, its relation to acid was only recognized in the 19th century by Rokitansky. Considerably more interest in the symptoms and complications of esophagitis has been evident over the last century, as gastroesophageal reflux disease displaced peptic ulceration and became the principal acid-related disease of our times. Of particular interest has been the recognition of the clinical significance of the previously overlooked extraesophageal manifestations of the disease such as laryngitis, asthma, and sleep disturbance. The evolution of highly effective medical therapy has over the last decade drastically reduced the need for surgical intervention for control of symptoms except under select conditions, especially volume-related reflux and children with refractory symptoms. The proton pump inhibitor class of drugs is indisputably the most effective overall form of management, while individual proton pump inhibitors appear to be equivalent in their efficacy. Issues that remain to be resolved include the management of nonerosive gastroesophageal reflux disease, the long-term dependence of many patients on acid-suppressing medication, and the recognition of atypical manifestations and rare but serious complications of gastroesophageal reflux disease. In this respect, Barrett's esophagus still presents a major biologic and management conundrum for the physicians and scientists alike.

Entities:  

Mesh:

Year:  2004        PMID: 15100517     DOI: 10.1097/00004836-200405000-00002

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  4 in total

1.  Long-term outcomes in pediatric-onset esophageal eosinophilia.

Authors:  Charles W DeBrosse; James P Franciosi; Eileen C King; Bridget K Buckmeier Butz; Allison B Greenberg; Margaret H Collins; J Pablo Abonia; Amal Assa'ad; Philip E Putnam; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2011-06-02       Impact factor: 10.793

2.  Assessment of quality of life after laparoscopic Nissen fundoplication in patients with gastroesophageal reflux disease.

Authors:  Deniz Balci; Ahmet G Turkcapar
Journal:  World J Surg       Date:  2007-01       Impact factor: 3.352

3.  Gastroesophageal reflux disease and physical activity.

Authors:  Pawel Jozkow; Dorota Wasko-Czopnik; Marek Medras; Leszek Paradowski
Journal:  Sports Med       Date:  2006       Impact factor: 11.136

4.  Evaluation of supplemental cautery during endoluminal gastroplication for the treatment of gastroesophageal reflux disease.

Authors:  Patrick Mosler; Ayman M Abdel Aziz; Karen Hieston; Charles Filipi; Glen Lehman
Journal:  Surg Endosc       Date:  2008-07-16       Impact factor: 4.584

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.